Blog
RSS FeedPosted by Michael Wonder on 07 May 2025
Omaveloxolone for the treatment of patients with Friedreich’s ataxia
6 May 2025 - NICE is unable to make a recommendation on the use of omaveloxolone (Skyclarys) for the treatment of ...
Posted by Michael Wonder on 04 May 2025
Government lists life-changing epilepsy drug fenfluramine on PBS
4 May 2025 - For the Sutton family, finding a drug that controlled four-year-old daughter Layla’s rare form of epilepsy was ...
Posted by Michael Wonder on 02 May 2025
DoH publishes revised agenda for the May 2025 PBAC meeting
2 May 2025 - The agenda for the May 2025 PBAC meeting has been updated. ...
Posted by Michael Wonder on 01 May 2025
Up to 1,000 women a year could benefit from new at-home treatment for endometriosis
1 May 2025 - Our final draft guidance recommends linzagolix (Yselty, Theramex) with hormonal add-back therapy for adults of reproductive age ...
Posted by Michael Wonder on 30 Apr 2025
SMC - April 2025 decisions
7 April 2025 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 28 Apr 2025
Come to grips’: fighting lymphoma from home
28 April 2025 - Australian patients with the most common form of lymphoma will for the first time have access ...
Posted by Michael Wonder on 28 Apr 2025
New position statement aims to guide the use of AI methods in health technology assessment
25 April 2025 - Canada’s Drug Agency has published a new position statement on the use of artificial intelligence methods ...
Posted by Michael Wonder on 27 Apr 2025
Ketamine nasal spray to become cheaper for Australians with treatment-resistant depression
28 April 2025 - A nasal spray that uses a form of ketamine to treat stubborn depression will be added ...
Posted by Michael Wonder on 27 Apr 2025
Dupilumab for the treatment of patients with moderate to severe chronic obstructive pulmonary disease
24 April 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 27 Apr 2025
Public Summary Documents (first time decisions not to recommend and deferrals) – December 2024 PBAC meeting
24 April 2025 - The Public Summary Documents (first-time decisions not to recommend and deferrals) from the December 2024 PBAC meeting ...
Posted by Michael Wonder on 27 Apr 2025
Recommendations made by the PBAC – March 2025
24 April 2025 - Recommendations made by the PBAC in March 2025 relating to the listing of medicines on the PBS ...
Posted by Michael Wonder on 27 Apr 2025
The role and value of real-world evidence in health technology decision-making in France, Germany, Italy, Spain, and the UK: insights on external control arms
22 April 2025 - Real-world evidence is increasingly used and accepted by health technology assessment (HTA) bodies as supportive evidence ...
Posted by Michael Wonder on 25 Apr 2025
Multiple myeloma drug subsidised after treatment costs ballooned
24 April 2025 - It’s one of the few cancers still considered incurable, and those diagnosed with multiple myeloma will likely ...
Posted by Michael Wonder on 18 Apr 2025
Canada’s Drug Agency announces new 5 year strategic plan
17 April 2025 - Canada’s Drug Agency announces a new 5-year strategic plan, Insight to Impact 2025–2030. ...
Posted by Michael Wonder on 16 Apr 2025
Eli Lilly issues warning for Australia as Trump signals pharma tariffs
15 April 2025 - Eli Lilly says it could pull tens of millions of dollars invested in Australian clinical trials unless ...